Alto Neuroscience director granted 10,958 stock options

Alto Neuroscience director Ramiro Sanchez received a grant of stock options for 10,958 shares of common stock.

Accepted by SEC EDGAR 05/14/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Alto Neuroscience director Ramiro Sanchez received a grant of stock options for 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. All 10,958 underlying shares will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. The options were issued under Alto Neuroscience’s Non-Employee Director Compensation Policy, and Sanchez paid no cash consideration for this award. Following this grant, he holds 10,958 derivative securities directly.

Insider Trade Summary

Grant/Award: 10,958 shares

Grant/Award 1 txn

Insider Sanchez Ramiro

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,958	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,958 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
2. F2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Key Figures

Option grant size: 10,958 options Exercise price: $24.63 per share Underlying shares: 10,958 shares +2 more

5 metrics

Option grant size 10,958 options Stock Option (right to buy) granted to director Ramiro Sanchez

Exercise price $24.63 per share Strike price for Alto Neuroscience common stock under the option

Underlying shares 10,958 shares Common Stock underlying the granted stock options

Total derivative holdings after grant 10,958 options Total stock options held directly following this transaction

Option expiration date May 11, 2036 Expiration of director stock option grant

Key Terms

Stock Option (right to buy), Non-Employee Director Compensation Policy, continuous service, Annual Meeting

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Non-Employee Director Compensation Policy financial

"issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy"

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

Annual Meeting financial

"the date of Issuer's next Annual Meeting following the date of grant"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanchez Ramiro

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CALIFORNIA 94041

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.63	05/12/2026		A		10,958		(1)	05/11/2036	Common Stock	10,958	$0(2)	10,958	D

Explanation of Responses:

1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)